Latest Us Market News

PainChek Limited has secured its first US customer, Jewish Home Family, just days after receiving FDA De Novo clearance for its AI-powered pain assessment app, marking a significant step into the $100 million US aged care market.

Orthocell Limited has reported a record $3 million quarterly revenue, driven by strong sales of its nerve repair product Remplir in Australia and Singapore, while advancing its rollout in the US and Canada ahead of schedule.

PainChek Limited has achieved a landmark FDA De Novo classification for its PainChek Adult App, positioning it as the first regulated medical device for pain assessment in the US aged care sector and opening a $100 million annual market opportunity.

Ovanti Limited has secured $8 million through a strategic share placement to accelerate its US Buy Now, Pay Later expansion, highlighted by a new three-year NASCAR sponsorship deal.

Mesoblast Limited reports a robust 66% increase in Ryoncil revenues for Q2 2025, driven by strong market adoption and new Medicare reimbursement codes.

Volt Resources is advancing its Alabama Graphite Refinery project to produce high purity graphite in the US, leveraging proven Ukrainian technology and targeting near-term commercial production with low capital costs and strong environmental credentials.

Acusensus Limited has landed its first major automated enforcement contract in the US with Connecticut, marking a significant milestone in its American growth strategy. The five-year deal, valued at US$22.6 million, will see the deployment of AI-enabled speed enforcement technology across work zones.

Micro-X Ltd has received a $5.08 million R&D tax incentive rebate for FY25, with an additional $0.31 million pending approval, reinforcing its innovation-driven growth in medical imaging technology.

Echo IQ’s application for a Category III CPT code was declined by the AMA, but the company is exploring reconsideration and new AI-specific coding frameworks to advance US reimbursement.

4DMedical has secured $22.6 million through the exercise of deep in-the-money options, significantly strengthening its cash position to support the commercial rollout of its CT – VQ™ respiratory imaging technology.

Hydralyte USA reports an 11% sales increase in Q3 2025, driven by strong summer demand and the launch of its innovative Hydralyte Plus Brain Support product featuring nootropics.

Cobram Estate Olives has successfully closed a $6.1 million Share Purchase Plan alongside a $2 million shortfall placement, fueling its US growth ambitions. The capital raise complements a recent $175 million institutional placement, underpinning the company’s strategic farmland acquisitions and olive grove developments in America.